Who are decitabine injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azacitidine Injection, Azacytidine, HAG Regimen, Azacitidine (AZA), Decitabine/Cedazuridine, Dacogen (decitabine) only, 5-Azacytidin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/decitabine-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

decitabine injection — Competitive Intelligence Brief

decitabine injection (decitabine injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DNA methyltransferase inhibitor. Area: Oncology.

marketed DNA methyltransferase inhibitor DNA methyltransferase (DNMT) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

decitabine injection (decitabine injection) — Janssen Korea, Ltd., Korea. Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
decitabine injection TARGET	decitabine injection	Janssen Korea, Ltd., Korea	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine Injection	Azacitidine Injection	Ascentage Pharma Group Inc.	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacytidine, HAG Regimen	Azacytidine, HAG Regimen	Shenzhen Second People's Hospital	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine (AZA)	Azacitidine (AZA)	Memorial Sloan Kettering Cancer Center	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Decitabine/Cedazuridine	Decitabine/Cedazuridine	Astex Pharmaceuticals, Inc.	phase 3	DNA methyltransferase inhibitor; hypomethylating agent	DNA methyltransferase (DNMT)
Dacogen (decitabine) only	Dacogen (decitabine) only	Eisai Inc.	phase 3	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
5-Azacytidin	5-Azacytidin	Technische Universität Dresden	phase 3	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DNA methyltransferase inhibitor class)

Ascentage Pharma Group Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Eisai Inc. · 1 drug in this class
Janssen Korea, Ltd., Korea · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
Shenzhen Second People's Hospital · 1 drug in this class
Technische Universität Dresden · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). decitabine injection — Competitive Intelligence Brief. https://druglandscape.com/ci/decitabine-injection. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab